Cannabinoid Therapy Shows Promise for Autoimmune Diseases, Biotech Firm Files Patent

NEW YORK, NY – November 17, 2025 – Raphael Pharmaceutical Inc. is making waves in the biotechnology sector with its development of a unique cannabinoid-based treatment for autoimmune diseases, specifically focusing on rheumatoid arthritis (RA). The company recently announced the filing of a provisional patent application for its proprietary technology and reports promising results from early clinical trials, positioning itself as a potential disruptor in a market dominated by large pharmaceutical companies.

A Novel Approach to Autoimmune Treatment

Raphael Pharmaceutical is pioneering a distinctly different approach to treating RA and other neutrophil-dominant autoimmune diseases. Unlike many existing therapies that rely on broad immunosuppression, their treatment utilizes a highly purified cannabinoid formulation without the psychoactive components THC and CBD. This formulation is designed to interact with the endocannabinoid system, specifically targeting immune cell function and reducing inflammation.

“The current landscape of RA treatment often involves managing symptoms and side effects,” explains an industry analyst familiar with the research. “A treatment that could potentially modulate the immune response without the drawbacks of traditional therapies would be a significant advancement.” The company’s lead product candidate, RaphaWell, is intended for oral delivery and has shown no adverse effects in initial clinical trials.

The research collaboration with Rambam Health Care Campus in Israel is central to Raphael’s innovation. Dr. Igal Louria-Hayon, who heads both the Medical Cannabis Research and Innovation Center at Rambam and serves as Raphael’s Chief Technology Officer, has been instrumental in developing and refining the treatment. This partnership provides access to cutting-edge research facilities, expertise, and crucial resources. "This isn't just about finding a drug; it's about understanding the intricate relationship between the endocannabinoid system and autoimmune disease,” notes a researcher involved in the project.

Positive Early Clinical Results and Patent Protection

Raphael Pharmaceutical recently completed a single-group clinical trial involving 12 adult participants with RA. The results, described as “promising,” indicated significant improvements in pain levels, sleep quality, and overall well-being after eight weeks of treatment with the cannabinoid formulation. Importantly, no adverse effects were reported. While the study was relatively small, the initial findings suggest a potential for efficacy and safety. The company is planning further clinical trials to validate these results and explore the treatment’s potential in other autoimmune diseases.

The filing of the provisional patent application marks a crucial step toward commercialization. This application covers the use of the cannabinoid technology for a range of neutrophil-dominant autoimmune diseases, including psoriatic arthritis, inflammatory bowel disease, and lupus. “Protecting our intellectual property is paramount,” states a company spokesperson. “This patent application demonstrates our commitment to innovation and our belief in the potential of this technology.” The patent application details a specific formulation and method of use, creating a barrier to entry for competitors.

Navigating a Competitive Market

The rheumatoid arthritis treatment market is substantial and expected to grow significantly in the coming decades. It is currently dominated by major pharmaceutical companies offering a range of therapies, including conventional disease-modifying antirheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs. Companies like AbbVie, Pfizer, and Johnson & Johnson hold significant market share.

Raphael Pharmaceutical, as a smaller biotech firm, faces the challenge of competing against these established players. However, the company believes its unique, THC/CBD-free formulation and focus on modulating the immune system, rather than suppressing it, could differentiate it in the market. “We’re not trying to compete head-to-head with the existing therapies,” explains an analyst. “We’re offering a different approach, one that may appeal to patients who are looking for a more holistic and targeted treatment.” The company’s strategy focuses on developing a cost-effective treatment with minimal side effects, addressing unmet needs in the RA patient population.

The company is currently trading on the OTCQB Venture Market and appears to be attracting investor interest as it progresses with its clinical trials and patent applications. While financial details are limited, the company is actively pursuing funding to support its research and development efforts. Analysts believe that successful completion of larger clinical trials and obtaining full patent protection will be critical to its long-term success.